General Shareholder Meeting 10th March9 Mar 2025 10:24
Oncimmune’s General Meeting tomorrow at 11:00 a.m. GMT will cover financial results and strategy, BOD and senior management expected to attend. Obviously there is an expectation for the major elefant in the room to be addressed here.
Lets get a little profile in place:
John Goold is an Independent Non-Executive Director at Oncimmune and chairs the Audit Committee. He owns about 1.55% of the company’s shares. Goold has a strong background in corporate finance, including time as CEO of Zeus Capital, where he helped raise a lot of capital. His financial experience seems quite valuable, especially now that Oncimmune is trying to secure more funding. As head of the Audit Committee, he’s also responsible for making sure the company’s finances are in order and transparent. @John - we are all on high alert!
Alistair Macdonald (Non-Executive Chair): With over 25 years in the pharma industry, he led Syneos Health as CEO, overseeing its formation through a merger and expanding its global reach. Not out of the question the company will be acquired. In fact that has always been on the cards.
Martin Gouldstone (Chief Executive Officer): Brings 30 years of corporate finance and business development experience in the CRO, healthcare, and pharmaceutical sectors. Senior positions at Owkin, Sensyne Health, Syneos One, and BenevolentAI. He has extensive experience in M&A, capital raising, and strategic partnerships. This to me is invaluable at this present moment.
Dr. Sally Waterman (Senior Independent Non-Executive Director): With over 30 years in senior executive roles across biopharmaceutical companies and service providers, Sally has led R&D, operations, and corporate development, contributing to multiple M&A transactions and IPOs. Is also on the Audit Committeed and Committe for Remuneration.
"It is the responsibility of the Board to ensure that the Group is managed for the long-term benefit of all shareholders and stakeholders, with effective and efficient decision-making. Corporate governance is an important aspect of this, reducing risk and adding value to our business."
In my view unless the company was in a critical condition other than trying to plug a funding gap for a limited period of time, the combined experience here should bode well for the business.
If anyone has the ability to attend, I'd encourage to do so in person at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT or to submit questions via forms on Oncimmunes website.
Sign In
Follow the stocks
